Researchers have known for some time that the risk of developing type 1 diabetes (T1D) can be detected by looking for the presence of specific autoantibodies. That knowledge has allowed JDRF to support TrialNet, a project that screens close relatives of people with T1D for risk factors and identifies individuals who would potentially benefit from early intervention.
↧